Targeting STARD3NL: A Potential Drug Target (G83930)

Target Name: STARD3NL

NCBI ID: G83930

STARD3NL

Targeting STARD3NL: A Potential Drug Target

STARD3NL (STARD3 N-terminal like, transcript variant 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The STARD3 gene is located on chromosome 16 and encodes a protein that is involved in stem cell maintenance and proliferation. The RNA molecule is derived from the gene and has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and survival.

The discovery of STARD3NL as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. The ability to target the STARD3 gene with small molecules or other therapeutic agents has the potential to treat a wide range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Function

The STARD3 gene encodes a protein that is 21 kDa in size and has four known splice variants: STARD3NL1, STARD3NL2, STARD3NL3, and STARD3NL4. All of these variants have the same N-terminus and a unique C-terminus that is responsible for the formation of a protein-protein interaction complex with other molecules.

The C-terminus of STARD3NL is a unique fusion of 21 amino acids that is known as the N-terminal hypervariable region (HVR). This HVR is involved in the formation of a protein-protein interaction complex with other molecules and has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and survival.

In addition to its role in protein-protein interaction, the N-terminal HVR of STARD3NL is also involved in the regulation of gene expression. This has been shown by experiments that demonstrate that the N-terminal HVR of STARD3NL can interact with various transcription factors, including NF-魏B, AP-1, and STAT3.

The potential drug target status of STARD3NL is supported by its expression in various tissues and cells, including human cancer cells, neuroglioblastoma cells, and human primary neurons. In addition, the STARD3NL gene has been shown to be expressed in various tissues and organs, including the brain, heart, and liver.

Drug targeting strategies

The use of small molecules to target the STARD3NL gene has the potential to treat a wide range of diseases. One approach to drug targeting is to use small molecules that can modulate the activity of the STARD3NL protein. This can be done by binding to specific residues on the protein or by modulating the activity of other molecules that interact with the protein.

Another approach to drug targeting is to use small molecules that can alter the expression of the STARD3NL gene. This can be done by inhibiting the activity of transcription factors that are involved in the regulation of gene expression, or by promoting the degradation of non-coding RNAs that are derived from the STARD3NL gene.

The development of small molecules that can effectively target the STARD3NL gene is an active area of research and has the potential to lead to new treatments for a wide range of diseases.

Conclusion

STARD3NL is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique N-terminal HVR and its involvement in the regulation of various cellular processes make it an attractive target for small molecules. Further research is needed to develop effective small molecules that can effectively target the STARD3NL gene and to determine its full potential as a drug.

Protein Name: STARD3 N-terminal Like

Functions: Tethering protein that creates contact site between the endoplasmic reticulum and late endosomes: localizes to late endosome membranes and contacts the endoplasmic reticulum via interaction with VAPA and VAPB (PubMed:24105263)

The "STARD3NL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD3NL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets